Filtered By:
Drug: Rosuvastatin

This page shows you your search results in order of date.

Order by Relevance | Date

Total 55 results found since Jan 2013.

Statins and immune-mediated necrotizing myopathy: Variability in the risk
CONCLUSION: Atorvastatin presents the highest risk of IMNM. Our data suggest that the occurrence of IMNM is a class effect.PMID:37625939 | DOI:10.1016/j.therap.2023.07.005
Source: Therapie - August 25, 2023 Category: Psychiatry & Psychology Authors: Thierry Trenque Jed Hadjoudj Agathe Trenque Federica Tralongo Salom é Martin Brahim Azzouz Source Type: research

Evaluation and subgroup analysis of the efficacy and safety of intensive rosuvastatin therapy combined with dual antiplatelet therapy in patients with acute ischemic stroke
ConclusionsWithout increasing bleeding and statin-associated adverse events, intensive rosuvastatin therapy plus 7-day DAPT significantly reduced the risk of recurrent stroke, especially for subgroups with high-risk factors.Clinical trial registration. China Clinical Trial Registration Center (ChiCTR1800017809).
Source: European Journal of Clinical Pharmacology - March 1, 2023 Category: Drugs & Pharmacology Source Type: research

Statin associated Muscular Adverse Effects
CONCLUSION: Early recognition of muscle symptoms is required to prevent rhabdomyolysis. Further researchare needed to completely elucidate the pathophysiology of statin-induced muscular adverse effects.PMID:36847228 | DOI:10.2174/1574886318666230227143627
Source: Current Drug Safety - February 27, 2023 Category: Drugs & Pharmacology Authors: Rania Kammoun Ons Charfi Ghozlane Lakhoua Ahmed Zaiem Riadh Daghfous Sarrah Kastalli Imen Aouinti Sihem El Aidli Source Type: research

Evaluation and subgroup analysis of the efficacy and safety of intensive rosuvastatin therapy combined with dual antiplatelet therapy in patients with acute ischemic stroke
ConclusionsWithout increasing bleeding and statin-associated adverse events, intensive rosuvastatin therapy plus 7-day DAPT significantly reduced the risk of recurrent stroke, especially for subgroups with high-risk factors.Clinical trial registration. China Clinical Trial Registration Center (ChiCTR1800017809).
Source: European Journal of Clinical Pharmacology - December 29, 2022 Category: Drugs & Pharmacology Source Type: research

Effects of rosuvastatin/ezetimibe on senescence of CD8+ T-cell in type 2 diabetic patients with hypercholesterolemia: A study protocol
Discussion: We will evaluate the effects of statin/ezetimibe on CD8 + T cell senescence. Statin/ezetimibe may exert a beneficial immunomodulatory effect.
Source: Medicine - November 25, 2022 Category: Internal Medicine Tags: Research Article: Study Protocol Clinical Trial Source Type: research

Drug –Drug Interaction of the Sodium Glucose Co-Transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data
ConclusionsReports of myopathy were not disproportionally higher among those using SGLT-2i with statins compared to SGLT-2i or statins alone at the class level. Further observational studies may be needed to better assess this interaction at the agent level.
Source: Drug Safety - March 5, 2022 Category: Drugs & Pharmacology Source Type: research

The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms
Clin Pharmacol Ther. 2022 Feb 12. doi: 10.1002/cpt.2557. Online ahead of print.ABSTRACTStatins reduce cholesterol, prevent cardiovascular disease, and are among the most commonly prescribed medications in the world. Statin-associated musculoskeletal symptoms (SAMS) impact statin adherence and ultimately can impede the long-term effectiveness of statin therapy. There are several identified pharmacogenetic variants that impact statin disposition and adverse events during statin therapy. SLCO1B1 encodes a transporter (SLCO1B1; alternative names include OATP1B1 or OATP-C) that facilitates the hepatic uptake of all statins. ABC...
Source: Clinical Pharmacology and Therapeutics - February 13, 2022 Category: Drugs & Pharmacology Authors: Rhonda M Cooper-DeHoff Mikko Niemi Laura B Ramsey Jasmine A Luzum E Katriina Tarkiainen Robert J Straka Li Gong Sony Tuteja Russell A Wilke Mia Wadelius Eric A Larson Dan M Roden Teri E Klein Sook Wah Yee Ronald M Krauss Richard M Turner Latha Palaniappan Source Type: research

Statin Induced Myopathy Among Patients Attending the National Center for Diabetes, endocrinology, & amp; genetics
CONCLUSIONS: The overall incidence of myopathy in patients taking statins was 27.8%. Myopathy was directly related to dose and type of statin used. The use of Fluvastatin XL 80 mg and Rosuvastatin 10 mg showed less incidence of myopathy compared with other statins.PMID:35145672 | PMC:PMC8818528 | DOI:10.1016/j.amsu.2022.103304
Source: Annals of Medicine - February 11, 2022 Category: Internal Medicine Authors: Waddah Abed Mousa Abujbara Anwar Batieha Kamel Ajlouni Source Type: research

Effects of Evolocumab Added to Moderate-Intensity Statin Therapy in Chinese Patients With Acute Coronary Syndrome: The EMSIACS Trial Study Protocol
Discussion: If the EMSIACS trial endpoints prove statistically significant, the evolocumab added to moderate-intensity statin therapy will have the potential to effectively lower subjects’ LDL-C levels, especially for the Chinese patients with acute phase ACS. However, if the risk of MACE is not significantly different between the two groups, we may extend follow-up time for secondary outcome when the clinical trial is over.Clinical trial registration: The study is registered to ClinicalTrials.gov (NCT04100434), which retrospectively registered on November 24, 2020.
Source: Frontiers in Physiology - November 23, 2021 Category: Physiology Source Type: research

Real-World Analyses of the Safety Outcome among a General Population Treated with Statins: An Asian Population-Based Study
CONCLUSIONS: Compared with atorvastatin and rosuvastatin, pitavastatin might be associated with a lower risk of safety events in Asians.PMID:34497171 | DOI:10.5551/jat.63076
Source: Journal of Atherosclerosis and Thrombosis - September 9, 2021 Category: Cardiology Authors: Jia-Ling Lin Po-Sheng Chen Hui-Wen Lin Liang-Miin Tsai Sheng-Hsiang Lin Yi-Heng Li Source Type: research